BRUSSELS, July 28 (Reuters) - The European Union has signed
a contract with GlaxoSmithKline for the supply of up to
220,000 treatments of its investigational monoclonal antibody
therapy sotrovimab against COVID-19, it said on Wednesday.
The contract has been signed by 16 of the 27 EU states. The
drug, which is being assessed by the EU medicines regulator and
is not authorised yet, can be used for the treatment of
coronavirus patients with mild symptoms who do not require
supplemental oxygen, the Commission said.
(Reporting by Francesco Guarascio @fraguarascio, editing by
Louise Heavens)